Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 7/20 | 0.46 |
| ▸ | LDHA | P00338 | 2/20 | 0.45 |
| ▸ | DNM1L | O00429 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | OGA | O60502 | 1/20 | 0.38 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.37 |
| ▸ | TRPC6 | Q9Y210 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15888536 | 0.82 | SMN1; SMN2 (0.50) | SMN1; SMN2ALDH1A1KDM4EGAACYP1A2 | |
| SCHEMBL12375315 | 0.80 | PTGER1 (0.73) | PTGER1 | |
| SCHEMBL20594891 | 0.80 | IRAK4 (0.51) | PTGER1LDHASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL10278349 | 0.80 | IRAK4 (0.51) | PTGER1LDHASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL29064995 | 0.79 | ADORA2A (0.43) | PTGER1LDHACYP1A2 | |
| SCHEMBL30295682 | 0.79 | ADORA2A (0.43) | PTGER1LDHACYP1A2 | |
| SCHEMBL21875377 | 0.78 | SMN1; SMN2 (0.52) | DNM1LSMN1; SMN2ALDH1A1KDM4EGAA | |
| SCHEMBL3556057 | 0.77 | L3MBTL1 (0.46) | DNM1LSMN1; SMN2ALDH1A1KDM4EGAA | |
| SCHEMBL13270380 | 0.76 | LDHA (0.47) | PTGER1LDHASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL13999772 | 0.75 | ALDH1A1 (0.39) | DNM1LSMN1; SMN2ALDH1A1GAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2206707-B1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2014-07-23 | — | — | EP | disclosed |
| US-8304547-B2 | Azolecarboxamide compound or salt thereof | ASTELLAS PHARMA INC. (JP) | 2012-11-06 | — | — | US | disclosed |
| US-8304547-B2 | Azolecarboxamide compound or salt thereof | ASTELLAS PHARMA INC. (JP) | 2012-11-06 | — | — | US | disclosed |
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20100249088-A1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-09-30 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249088-A1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | TRPV1, FGFR3, GPR17 | PTGER1 877/4885LDHA 3123/4885DNM1L 2310/4885 |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | GPR17, NTRK1, TRPV1 | PTGER1 1115/4885LDHA 2568/4885DNM1L 2818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.